13F filerCIK 1536411 ↗

Duquesne Family Office

You are looking at Q2 2025. See the latest, Q3 2026 →

Reported value

$4.07B

+33% on the quarter before

Positions

69

35 new, 18 sold out

Top 10

50.5%

of the value

Est. gain

+$466.8M

on stocks held all quarter

Est. return

+21.3%

on those stocks since Q1 2025

Filed

Aug 15, 2025

On SEC EDGAR ↗

Positions as of Jun 30, 2025, from Duquesne Family Office's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2025. Striped tiles are options.

45 others23%
Natera Inc13%
Teva Pharmaceutical Inds Ltd6.6%
Insmed Inc5.6%
Woodward Inc5.1%
TSMC4.3%
Philip Morris Intl Inc3.7%
MercadoLibre3.4%Entegris3.3%
Coupang Inc3.0%
Flutter Entmt Plc2.8%
Coherent Corp2.5%
DocuSign2.5%Microsoft2.5%
Roku Inc2.4%
Verona Pharma Plc2.3%
Eli Lilly1.9%
Warner Bros Discovery Inc1.8%
Eqt Corp1.8%
Ishares Tr1.8%
Citigroup Inc1.4%
SPDR S&P 500 ETF Tr1.4%
Select Sector SPDR Tr1.3%
Restaurant Brands Intl Inc1.2%
Sea1.2%

Largest buys

Since Q1 2025, sized at quarter-end prices.

  1. Entegris~$132.7MNew, 0.0% → 3.3% of the portfolio+1,645,885 shares
  2. Microsoft~$99.9MNew, 0.0% → 2.5% of the portfolio+200,930 shares
  3. Insmed Inc~$89.0MAdded, 3.4% → 5.6% of the portfolio+884,385 shares
  4. Warner Bros Discovery Inc~$74.9MNew, 0.0% → 1.8% of the portfolio+6,537,160 shares
  5. Ishares TrCALL~$72.3MNew, 0.0% → 1.8% of the portfolio+335,000 underlying
  6. Citigroup Inc~$56.7MNew, 0.0% → 1.4% of the portfolio+666,300 shares
  7. SPDR S&P 500 ETF TrCALL~$55.6MNew, 0.0% → 1.4% of the portfolio+90,000 underlying
  8. Roku Inc~$53.3MAdded, 1.1% → 2.4% of the portfolio+606,900 shares
  9. Select Sector SPDR Tr~$51.6MNew, 0.0% → 1.3% of the portfolio+985,300 shares
  10. Restaurant Brands Intl Inc~$49.8MNew, 0.0% → 1.2% of the portfolio+751,010 shares

Largest sells

Since Q1 2025, sized at quarter-end prices.

  1. Coupang Inc~$155.7MCut, 6.7% → 3.0% of the portfolio−5,197,210 shares
  2. Coherent Corp~$94.9MCut, 4.7% → 2.5% of the portfolio−1,064,230 shares
  3. Woodward Inc~$61.0MCut, 6.5% → 5.1% of the portfolio−248,840 shares
  4. Natera Inc~$53.6MCut, 15.7% → 12.8% of the portfolio−317,140 shares
  5. Philip Morris Intl Inc~$52.7MCut, 5.7% → 3.7% of the portfolio−289,293 shares
  6. Ccc Intelligent Solutions Hl~$43.2MCut, 1.7% → 0.2% of the portfolio−4,587,095 shares
  7. Ypf Sociedad Anonima~$43.1MCut, 2.4% → 0.5% of the portfolio−1,371,395 shares
  8. Barclays Plc~$42.2MCut, 1.9% → 0.7% of the portfolio−2,267,355 shares
  9. Delta Air Lines Inc DelCALL~$41.4MSold out, 1.4% → 0.0% of the portfolio−949,500 underlying
  10. Capital One Finl Corp~$35.4MSold out, 1.2% → 0.0% of the portfolio−197,670 shares

Holdings

As of Jun 30, 2025; changes in shares since Mar 31, 2025.

Positions, sorted by share of the portfolio
HoldingValue
Natera IncCOM · shares −9.3% · price +19.5%12.8%$521.2M+$84.9M
Teva Pharmaceutical Inds LtdSPONSORED ADS · shares +7.3% · price +9.0%6.6%$267.6M+$20.7M
Insmed IncCOM PAR $.01 · shares +65% · price +31.9%5.6%$226.8M+$33.3M
Woodward IncCOM · shares −23% · price +34.3%5.1%$208.1M+$53.1M
TSMCSPONSORED ADS · shares +28% · price +36.4%4.3%$173.3M+$36.2M
Philip Morris Intl IncCOM · shares −26% · price +14.7%3.7%$148.6M+$19.1M
MercadoLibreCOM · shares 0% · price +34.0%3.4%$140.4M+$35.6M
EntegrisCOM · shares New3.3%$132.7M—
Coupang IncCL A · shares −56% · price +36.6%3.0%$123.0M+$33.0M
Flutter Entmt PlcSHS · shares +7.4% · price +29.0%2.8%$115.8M+$24.3M
Coherent CorpCOM · shares −48% · price +37.4%2.5%$103.3M+$28.1M
DocuSignCOM · shares +20% · price −4.3%2.5%$100.5M−$3.8M
MicrosoftCOM · shares New2.5%$99.9M—
Roku IncCOM CL A · shares +123% · price +24.8%2.4%$96.7M+$8.6M
Verona Pharma PlcSPONSORED ADS · shares 0% · price +49.0%2.3%$94.8M+$31.2M
Eli LillyCOM · shares +6.2% · price −5.6%1.9%$78.5M−$4.4M
Warner Bros Discovery IncCOM SER A · shares New1.8%$74.9M—
Eqt CorpCOM · shares +46% · price +9.2%1.8%$73.1M+$4.2M
Ishares TrCALLRUSSELL 2000 ETF · shares New1.8%$72.3M—
Citigroup IncCOM NEW · shares New1.4%$56.7M—
SPDR S&P 500 ETF TrCALLTR UNIT · shares New1.4%$55.6M—
Select Sector SPDR TrFINANCIAL · shares New1.3%$51.6M—
Restaurant Brands Intl IncCOM · shares New1.2%$49.8M—
SeaSPONSORD ADS · shares New1.2%$49.5M—
Nu Hldgs LtdORD SHS CL A · shares New1.2%$46.9M—
Total 69 positions100%$4.07B+$466.8M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q1 2025 to Q2 2025: 34 stocks held throughout, up $466.8M (+21.3%).

  1. Natera Inc+$84.9M+19%
  2. Woodward Inc+$53.1M+34%
  3. TSMC+$36.2M+36%
  4. MercadoLibre+$35.6M+34%
  5. Insmed Inc+$33.3M+32%
  6. Banco Macro Sa−$1.2M−7%
  7. Newamsterdam Pharma Company−$1.9M−12%
  8. Ypf Sociedad Anonima−$2.5M−10%
  9. DocuSign−$3.8M−4%
  10. Eli Lilly−$4.4M−6%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$6.00B$3.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$4.47B−14%SEC ↗
Q2 2026$5.21B+54%SEC ↗
Q1 2026$3.38B−25%SEC ↗
Q4 2025$4.49B+11%SEC ↗
Q3 2025$4.06B−0%SEC ↗
Q2 2025$4.07B+33%SEC ↗
Q1 2025$3.06B−18%SEC ↗
Q4 2024$3.72B+26%SEC ↗
Q3 2024$2.95B+1%SEC ↗
Q2 2024$2.92B−34%SEC ↗
Q1 2024$4.39B+31%SEC ↗
Q4 2023$3.35B+20%SEC ↗
Q3 2023$2.79B−3%SEC ↗
Q2 2023$2.87B+25%SEC ↗
Q1 2023$2.31B+14%SEC ↗
Q4 2022$2.02B+15%SEC ↗
Q3 2022$1.76B+28%SEC ↗
Q2 2022$1.38B−40%SEC ↗
Q1 2022$2.31B−16%SEC ↗
Q4 2021$2.76B−10%SEC ↗
Q3 2021$3.08B−24%SEC ↗
Q2 2021$4.04B−11%SEC ↗
Q1 2021$4.53B+22%SEC ↗
Q4 2020$3.71B+8%SEC ↗
Q3 2020$3.44B+5%SEC ↗
Q2 2020$3.27B+32%SEC ↗
Q1 2020$2.47B−28%SEC ↗
Q4 2019$3.41B+33%SEC ↗
Q3 2019$2.57B−24%SEC ↗
Q2 2019$3.37B−2%SEC ↗
Q1 2019$3.45B+100%SEC ↗
Q4 2018$1.73B−18%SEC ↗
Q3 2018$2.10B+2%SEC ↗
Q2 2018$2.07B+14%SEC ↗
Q1 2018$1.81B−9%SEC ↗
Q4 2017$1.98B−10%SEC ↗
Q3 2017$2.20B+18%SEC ↗
Q2 2017$1.87B+22%SEC ↗
Q1 2017$1.52B+49%SEC ↗
Q4 2016$1.03B−9%SEC ↗
Q3 2016$1.13B+30%SEC ↗
Q2 2016$870.7M−35%SEC ↗
Q1 2016$1.34BSEC ↗

Subscribe to TheInference for free